New York, NY -- (ReleaseWire) -- 03/27/2013 --Ziopharm Oncology Inc. (NASDAQ: ZIOP) traded in the range of $1.70 and $1.91 during its latest trading session. The stock had opened at $1.77 and is at $1.79, down 1.37 percent from its previous close. Ziopharm Oncology recorded the volume of 3.76 million shares. Its average daily trading volume stands at 2.91 million shares. Its MACD chart shows neutral trend and the stock may go as high as $1.95 in the coming sessions. Its first support level stands at $1.65, breaching this level, the stock may tumble to $1.50.
Ziopharm Oncology specializes in developing and marketing cancer therapies.
Find out more on ZIOP here:
Delcath Systems Inc. (NASDAQ: DCTH) stock is at $1.66, down 1.19 percent from its previous close. The stock opened the session at $1.68 and touched its highest price point at $1.72. Delcath Systems stock’s lowest price point for the session stood at $1.66. The stock is likely to maintain its neutral trend in the near term and medium term. Delcath Systems stock may touch $1.75 level in the coming trading sessions. On the downside, the stock has support at $1.58.
Delcath Systems deals in developing therapies and it also develops medical devices. The company focuses on oncology issues including liver cancer.
Find out more on DCTH here:
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit: http://www.wallstreetreport.net/disclaimer-2/
WALL STREET REPORT